Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Abortion Pill Reversal topic
No spam. Unsubscribe anytime.
Debate over abortion‑pill reversal grows; bill would restrict promotion and prescribe discipline, critics say
Summary
A proposed restriction on promotion and prescription of abortion‑pill reversal prompted conflicting testimony: advocates for access described positive cases, while medical groups urged caution and requested formal clinical guidance rather than disciplinary rules.
The committee heard competing testimony on a bill that would limit deceptive trade practices and could discipline clinicians who prescribe or promote so‑called abortion‑pill reversal protocols.
Proponents described cases in which patients who initially took mifepristone later changed their minds and received high‑dose progesterone with apparent pregnancy continuation. Paul D'Beesi, a research analyst, cited historical studies and recent case series and urged that patients have access to progesterone as a salvage option.
Opponents including medical organizations, Planned Parenthood and some clinical witnesses warned that published evidence for routine effectiveness is limited and that guidance from medical authorities is needed to standardize practice. They said regulatory restrictions that bar clinicians from responding to patients’ requests could harm patient‑clinician relationships and raised concerns about politicizing clinical practice.
The Department of Public Health’s prior communications were referenced during testimony; one witness said public records did not show complaints that motivated DPH’s earlier cautionary guidance. The committee asked parties to submit clinical data and the DPH rationale in writing for the record; no vote was taken.
